Floatz logo

Nivolumab

Malignant Ascites

China Medical University Hospitalmonoclonal_antibodyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Malignant Ascites cohort.

Asset / SponsorPhaseRating
Catumaxomab
Neovii Biotech
Phase 2/3BB
5,5'-DINITROSALICIL
Wuhan YZY Biopharma Co., Ltd.
Phase 3BB
Metformin
University of Chicago
Phase 2B
Serplulimab
Second Affiliated Hospital of Soochow University
Phase 1/2CC
Molgramostim
Second Affiliated Hospital of Soochow University
Phase 1/2CC

View all 14 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →